CRYO CELL INTERNATIONAL INC (CCEL)
CRYO CELL INTERNATIONAL INC (CCEL)
| Cash Flow | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|---|
| Impairment of public inventory | NaN | 4,358,834 | NaN | NaN |
| Impairment of investment - tianhe stock | NaN | 0 | 0 | 0 |
| Loss on sale of property and equipment | NaN | 0 | -633 | -47,671 |
| Net income | 47,108 | -3,817,433 | 749,408 | 638,640 |
| Depreciation and amortization expense | 244,212 | 243,011 | 244,090 | 498,141 |
| Losses on marketable securities | -240,458 | -201,648 | -193,886 | -410,733 |
| Unrealized gain on interest rate swap contract | NaN | 0 | 0 | 0 |
| Compensatory element of stock options | 158,549 | 42,903 | 36,780 | 337,418 |
| Provision for doubtful accounts | 213,341 | 88,598 | 413,611 | 366,586 |
| Deferred income tax benefit | NaN | -2,818,688 | NaN | NaN |
| Amortization of debt issuance costs | 5,136 | 5,165 | 5,192 | 10,465 |
| Amortization of operating lease right-of-use asset | 97,787 | 87,222 | 109,540 | 186,114 |
| Accounts receivable | 182,853 | 101,398 | 315,517 | -11,034 |
| Prepaid expenses | -178,529 | -44,712 | -3,415 | -15,710 |
| Other liabilities | NaN | 0 | 0 | 0 |
| Inventory | -51,803 | 23,540 | -21,511 | -58,219 |
| Other current assets | -24,435 | 288,991 | -47,339 | -62,265 |
| Deposits and other assets, net | 112,647 | 7,320 | 30,450 | 61,694 |
| Accounts payable | 430,737 | 258,850 | 370,475 | 370,932 |
| Accrued expenses | -1,390,667 | 1,993,452 | -389,123 | -3,136,174 |
| Operating lease liability | -109,654 | -106,957 | -114,728 | -203,016 |
| Deferred revenue | 755,553 | 1,120,745 | 1,190,654 | 2,048,033 |
| Net cash from operating activities | 651,827 | 1,280,813 | 2,536,716 | 1,661,077 |
| Purchases of property and equipment | 67,065 | 67,226 | 38,788 | 124,461 |
| Sale of property and equipment | NaN | 0 | 0 | 115,000 |
| Payment of duke license agreement | NaN | 0 | 0 | 0 |
| Proceeds from liquidation of marketable securities | NaN | 0 | 0 | NaN |
| Purchases of marketable securities | 507,304 | 487,619 | 585,896 | 2,574,249 |
| Sale of marketable securities | 593,473 | 265,196 | 1,729,285 | 793,426 |
| Net cash from (used) in investing activities | 19,104 | -289,649 | 1,104,601 | -1,790,284 |
| Treasury stock purchases | NaN | 0 | 80,883 | 88,619 |
| Repayments of note payable | 40,290 | 37,340 | 35,819 | 74,416 |
| Repayment of line of credit | 1,900,000 | 2,900,000 | 3,420,000 | 3,700,000 |
| Proceeds from the exercise of stock options | NaN | 0 | 23,101 | NaN |
| Proceeds from line of credit | 1,200,000 | 2,000,000 | 0 | 6,800,000 |
| Dividends paid | 0 | 0 | 0 | 3,231,227 |
| Proceeds from swap termination | NaN | 0 | 0 | 0 |
| Net cash (used in) provided by financing activities | -740,290 | -937,340 | -3,513,601 | -294,262 |
| Decrease in cash and cash equivalents | -69,359 | 53,824 | 127,716 | -423,469 |
| Cash and cash equivalents - beginning of period | 319,031 | 265,207 | 560,960 | NaN |
| Cash and cash equivalents - end of period | 249,672 | 319,031 | 265,207 | NaN |